Literature DB >> 7318841

Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.

G E Janka, P Möhring, M Helmig, R J Haas, K Betke.   

Abstract

Ten children with transfusion dependent anemias (thalassemia, sideroblastic anemia, congenital pure red cell aplasia) received either intravenous desferrioxamine (DF) in increasing doses up to 450 mg/kg at the time of transfusion or daily subcutaneous DF up to 110 mg/kg on an outpatient basis. No patient on intravenous DF reached a negative iron balance. All children with a subcutaneous DF dose of more than 60 mg/kg obtained a negative iron balance with a net iron excretion (transfusion iron already substracted) between 206 to 810 mg (mean 496 mg) monthly. The effectiveness of regular subcutaneous DF on liver storage iron could be confirmed in 4 patients by liver biopsy, showing a decrease between 40-60% iron after 12-14 months of chelation therapy. So far the daily iron excretion has remained constant with a given dose of DF over a period up to 15 months. Even if poor compliance in some patients is taken into account, it is possible with this method of treatment to prevent further accumulation of iron in chronically transfused children.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7318841     DOI: 10.1007/bf00443259

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  18 in total

1.  Total management of thalassaemia major.

Authors:  B Modell
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

2.  Long-term desferrioxamine therapy in thalassemia.

Authors:  C B Modell; J Beck
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

3.  Clinical and laboratory studies on the action of desferrioxamine.

Authors:  R L Cumming; J A Millar; J A Smith; A Goldberg
Journal:  Br J Haematol       Date:  1969-09       Impact factor: 6.998

4.  Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.

Authors:  M Weiner; M Karpatkin; D Hart; C Seaman; S K Vora; W L Henry; S Piomelli
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

5.  Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects.

Authors:  M R Summers; A Jacobs; D Tudway; P Perera; C Ricketts
Journal:  Br J Haematol       Date:  1979-08       Impact factor: 6.998

6.  Serum ferritin, liver iron stores, and liver histology in children with thalassaemia.

Authors:  S de Virgiliis; G Sanna; G Cornacchia; F Argiolu; V Murgia; M Porcu; A Cao
Journal:  Arch Dis Child       Date:  1980-01       Impact factor: 3.791

7.  Reassessment of the use of desferrioxamine B in iron overload.

Authors:  R D Propper; S B Shurin; D G Nathan
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

8.  Serum ferritin in children with thalassaemia regularly transfused.

Authors:  E A Letsky; F Miller; M Worwood; D M Flynn
Journal:  J Clin Pathol       Date:  1974-08       Impact factor: 3.411

9.  Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.

Authors:  M A Hussain; N Green; D M Flynn; A V Hoffbrand
Journal:  Lancet       Date:  1977-05-07       Impact factor: 79.321

10.  Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload.

Authors:  A Jacobs; F Miller; M Worwood; M R Beamish; C A Wardrop
Journal:  Br Med J       Date:  1972-10-28
View more
  3 in total

1.  Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.

Authors:  E A Llados i Vallory; R Girot; G Lenoir; M Payet; P Houze; R Bourdon
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

2.  Sideroachrestic anemia with iron loading: treatment with desferrioxamine.

Authors:  W G Zoller; R Hehlmann
Journal:  Klin Wochenschr       Date:  1986-05-02

3.  Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review.

Authors:  J Caro; Krista F Huybrechts; Traci C Green
Journal:  BMC Blood Disord       Date:  2002-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.